An investigation for current long-term investors in shares of Orexigen Therapeutics, Inc. (NASDAQ:OREX) over potential wrongdoing by certain officers and directors of Orexigen Therapeutics was announced and NASDAQ:OREX stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com

San Diego, CA -- (SBWire) -- 05/14/2013 --An investigation on behalf of current long-term stockholders of shares of Orexigen Therapeutics, Inc. (NASDAQ:OREX) was announced concerning whether certain Orexigen Therapeutics officers and directors possibly breached their fiduciary duties in connection with certain statements.

Investors who are current long-term stockholder of shares of Orexigen Therapeutics, Inc. (NASDAQ:OREX), have certain options and should contact the Shareholders Foundation at mail(at)shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Orexigen Therapeutics officers and directors breached their fiduciary duties and caused damage to the company and its shareholders by, among other things, failing to implement adequate internal controls.

Orexigen Therapeutics, Inc. reported that its annual Total Revenue declined from $4.40 million in 2011 to $3.43 million in 2012 and that its respective Net Loss increased from $28.06 million to $90.09 million.

Shares of Orexigen Therapeutics, Inc. grew from $1.28 per share in Sept. 2011 to $7.06 per share in July 2013.

On May 13, 2013, NASDAQ:OREX shares closed at $6.21 per share.

Those who purchased shares of Orexigen Therapeutics, Inc. (NASDAQ:OREX), have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Trevor Allen
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com